as 03-25-2025 12:30pm EST
Stocks
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
Upcoming Earnings Alert:
Get ready for potential market movements as QILIAN INTERNATIONAL HLDG GROUP LTD BGM prepares to release earnings report on 01 Apr 2025.
Founded: | 2019 | Country: | China |
Employees: | N/A | City: | N/A |
Market Cap: | 962.5M | IPO Year: | 2021 |
Target Price: | N/A | AVG Volume (30 days): | 24.6K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.20 | EPS Growth: | N/A |
52 Week Low/High: | $2.70 - $14.78 | Next Earning Date: | 04-01-2025 |
Revenue: | $25,097,951 | Revenue Growth: | -45.99% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
BGM Breaking Stock News: Dive into BGM Ticker-Specific Updates for Smart Investing
PR Newswire
7 days ago
PR Newswire
a month ago
PR Newswire
a month ago
PR Newswire
3 months ago
PR Newswire
3 months ago
GlobeNewswire
3 months ago
PR Newswire
3 months ago
PR Newswire
4 months ago
The information presented on this page, "BGM QILIAN INTERNATIONAL HLDG GROUP LTD - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.